Drug intelligence / Profile preview

Aerovid

Development stage: Unknown
Lead developer: Aquilon Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

Aerovid is an inhaled therapeutic candidate developed by Aquoralon Pharmaceuticals (Aquilon Pharma) for the treatment of viral infections. The program utilizes a proprietary cyclodextrin-based formulation technology, specifically employing the excipient HPBetadex, to enhance the solubility and delivery of anti-infective agents to the deep lung. Aquilon Pharma focuses on reformulating known small molecules to improve their pharmacokinetic profiles and deposition when delivered via nebulizers, dry powder inhalers (DPI), or soft mist inhalers. As of 2023, Aerovid is listed in Phase 1 clinical development.

Other names: AEROVID

Beyond the preview

Go deeper on Aerovid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerovid.

Explore the full profile